$115.42
+10%Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. Its lead product candidate is QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania.
Chief Financial Officer & Treasurer
Chief Operating Officer
Compensation
$638,960
Chief Scientific Officer
Compensation
$530,435
Founder, President, Chief Executive Officer & Director
Compensation
$901,066
SVice President of CMC & Technical Operations
Senior Vice President of Clinical Operations
Vice President of Corporate Development & New Product Planning
During the last 12 months, insiders have purchased $2.47M and sold $1.66M worth of PVLA shares, resulting in $807K of net buying activity.
445
49.97K
7.1K
826.92K
-777K
-$777K
6.4K
800.00K
7.9K
707.36K
+93K
+$93K
0
0.00
1.5K
128.58K
-129K
-$129K
61.8K
1.62M
0
0.00
+1.6M
+$1.62M
Jenkins George M
Director
$874K
Heron Elaine J
Director
$624K
Kiritsy Christopher P
Director
$324K
Wessel Tadd S.
Director
$324K
Davis Todd C
Director
$324K
Goin Kathleen
Officer: Chief Operating Officer
$1.66M
Moderately bullish with $807K net buying. Insiders show cautious optimism through measured share purchases.
Positive buy/sell ratio. Buying exceeds or matches selling, indicating net positive insider sentiment.
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
5 insider buyers vs. 1 sellers. Broad-based buying across management team suggests widespread confidence.
Broad-based insider buying: When multiple insiders independently decide to purchase shares, it often reflects genuine confidence rather than coordinated optics. This pattern deserves attention, especially if buying followed a price decline.
PVLA - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 30, 2026 | June 10, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 30, 2025 | June 10, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | November 06, 2024 | December 02, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 28, 2023 | June 21, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 29, 2022 | June 22, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 29, 2021 | June 25, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 28, 2020 | June 23, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | June 18, 2019 | June 18, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | June 14, 2018 | June 14, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | May 16, 2017 | June 30, 2017 | 2017 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.